GNRH1 and neoplasm: The group of Prof. G. Mező has achieved a great progression in the field of PDCs the last years working mostly on GnRH-III (Glp-His-Trp-Ser-His-Asp-Trp-Lys-Pro-Gly-NH2), which was exploited as a tumor homing device for drug targeting 10 years ago [111].